iTeos Therapeutics, Inc. (ITOS)
Automate Your Wheel Strategy on ITOS
With Tiblio's Option Bot, you can configure your own wheel strategy including ITOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ITOS
- Rev/Share 0.8094
- Book/Share 13.0298
- PB 0.7748
- Debt/Equity 0.009
- CurrentRatio 14.1331
- ROIC -0.2685
- MktCap 386374011.0
- FreeCF/Share -2.3203
- PFCF -3.8509
- PE -3.337
- Debt/Assets 0.0077
- DivYield 0
- ROE -0.2136
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ITOS | Wedbush | Outperform | Neutral | -- | $12 | May 28, 2025 |
| Downgrade | ITOS | Wells Fargo | Overweight | Equal Weight | -- | $12 | May 28, 2025 |
| Downgrade | ITOS | H.C. Wainwright | Buy | Neutral | -- | -- | May 14, 2025 |
| Downgrade | ITOS | Leerink Partners | Outperform | Market Perform | -- | $9 | May 14, 2025 |
| Downgrade | ITOS | JP Morgan | Overweight | Neutral | -- | -- | May 13, 2025 |
News
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share (“iTeos Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs …
Read More
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability.
Read More
About iTeos Therapeutics, Inc. (ITOS)
- IPO Date 2020-07-24
- Website https://www.iteostherapeutics.com
- Industry Biotechnology
- CEO Michel Detheux
- Employees 173